The endosome–lysosome pathway and information generation in the immune system  by Watts, Colin
Biochimica et Biophysica Acta 1824 (2012) 14–21
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbapapReview
The endosome–lysosome pathway and information generation in the
immune system☆
Colin Watts ⁎
Division of Cell Signalling & Immunology, College of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK☆ This article is part of a Special Issue entitled:
discovery of lysosome.
⁎ Tel.: +44 1382 384233; fax: +44 1382 381098.
E-mail address: c.watts@dundee.ac.uk.
1570-9639 © 2011 Elsevier B.V.
doi:10.1016/j.bbapap.2011.07.006
Open access under CC BYa b s t r a c ta r t i c l e i n f oArticle history:
Received 3 June 2011
Received in revised form 6 July 2011
Accepted 7 July 2011
Available online 18 July 2011
Keyword:
Endosome–lysosome pathwayFor a long time the lysosomal pathway was thought to be exclusively one for catabolism and recycling of
material taken up by endocytosis from the external milieu or from the cytosol by autophagy. At least in the
immune system it is clear now that endo/lysosomal proteolysis generates crucially important information, in
particular peptides that bind class II MHC molecules to create ligands for survey by the diverse antigen
receptors of the T lymphocyte system. This process of antigen processing and presentation is used to display
not only foreign but also self peptides and therefore is important for ‘self’ tolerance as well as immunity to
pathogens. Some cells, macrophages and particularly dendritic cells can load peptides on class I MHC
molecules in the endosome system through the important, though still not fully characterised, pathway of
cross-presentation. Here I try to provide a brief review of how this area developed focussing to some extent
our own contributions to understanding the class II MHC pathway. I alsomention brieﬂy recent work of others
showing that proteolysis along this pathway turns out to regulate immune signalling events in the innate
immune system such as the activation of some members of the Toll-like receptor family. Finally, our recent
work on the endo/lysosome targeted protease inhibitor cystatin F, suggests that auto-regulation of protease
activity in some immune cells occurs. This article is part of a Special Issue entitled: Proteolysis 50 years after
the discovery of lysosome.Proteolysis 50 years after the
 license.© 2011 Elsevier B.V. Open access under CC BY license.1. Introduction
In 1984 Christian deDuve published amonograph entitled: ‘A guided
tour of the living cell’ [1]. Itwas based on a series of Christmas lectures he
gave at Rockefeller University in the mid to late 70s to high school
students. In the book, as no doubt in the lectures, he takes his young
audience on a tour of the cell's diverse compartments encouraging them
to imagine that they are ‘cytonauts’ exploring the cell's myriad internal
structures. The book vividly describes the cell'smajor sub-compartments
and what was then known about them. In his chapter on lysosomes he
states that:
‘A few years ago, nobody in his senses would have dared to enter a
cell by the endocytic route unless there were some strict
guarantee that the lysosomal compartment would be by-
passed…even if you escaped being burned by the acid or cut to
pieces by the hydrolases, you would remain forever trapped
within a membraneous prison’[1].However, de Duve goes on to say that this view is changing and
that there may be escape routes from the endo/lysosomal pathway.
He does not give speciﬁc examples and not being an immunologist he
probably was not thinking of experiments recently published in the
then embryonic ﬁeld of antigen presentation. In the early 1980s the
lab of Emil Unanue, studying T cell responses to the pathogen Listeria
monocytogenes, showed that before Listeria monocytogenes reactive T
lymphocytes could bind to macrophages exposed to this bacterium a
30–60 min period was required during which the bacteria were
partially catabolised following uptake into the macrophage phagoly-
sosomal system [2]. The clear implication was that an intracellular
processing event was needed before the T cells could recognised
Listeria exposed macrophages and that some part of the bacterium
was presumably being returned to the cell surface. Remarkably, T cells
were still able to bind to the macrophages when they were ﬁxed with
aldehyde after the period of Listeria catabolism but not if the cells
were ﬁxed before exposure to the bacteria. Moreover, lysosomotropic
agents such as chloroquine and ammonia, which reduced antigen
catabolism, also reduced antigen presentation to T cells but again, not
if applied after the period of Listeria uptake [3]. Unanue and colleagues
speculated that this ‘processed antigen’ might be associated with the
products of what were then known as I region genes and which we
now identify as class II MHC molecules. This work followed pioneering
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in T cell responses to protein antigens: simply put, genes at the Major
Histocompatibility Complex (MHC) locus controlled whether or not a
particular inbred mouse strain responded to a protein or peptide antigen
[4-6].
2. Early studies on antigen processing in the endo/lysosomal system
The work of Unanue's lab and other early studies indicated that
complete destruction in the lysosomal system can indeed be avoided
and that the material salvaged provides vitally important biological
information. The next challenge was to determine what ‘antigen
processing’ really entailed. Other model ‘antigens’, more tractable
than Listeria, such as ovalbumin and hen egg lysozyme began to be used
tomove things forward. In a key study Grey and colleagues showed that
aldehyde ﬁxed antigen presenting cells (APC) could not present
denatured ovalbumin to T cells but could present either chemically or
enzymatically generated ovalbumin fragments [7]. These studies were
among the ﬁrst to show that partial antigen fragmentation was a
necessary and sufﬁcient event for T cell recognition and opened theway
to deﬁning the precise peptide sequences or ‘epitopes’ that T cells
recognised. Soon after, experiments demonstrating direct binding of
processed or synthetic antigenic peptides to isolated MHC class II
molecules were performed demonstrating for the ﬁrst time the likely
biochemical basis ofMHC restriction [8].When theﬁrst crystal structure
of a class I MHC molecule was solved in 1987 [9]and that for a class II
MHC molecule a few years later [10], both showing clear evidence of
electron density due to peptide in the groove between the two long
α-helices, the endpoint of antigen processing was ﬁnally clear. In the
intervening years many of the details of antigen processing leading to
antigen presentation have been worked out, as of course has the
molecular cell biology of membrane and protein trafﬁc along the
endocytic pathway.
This brief article is not an in depth review of this area which would
require more space, more focus and less emphasis on our own work but
rather, is a personal overview of some early and more recent de-
velopments that may be of interest to those from outside the ﬁeld.
Classical class IMHCpeptide loading is not discussed since it takes place in
the endoplasmic reticulum (ER) but so called cross-presentation on class I
MHCmolecules is mentioned since increasing evidence suggests that this
non-canonical mode of peptide loading can take place in phagosomes or
endosomes. At the end I mention some recent work from our lab which
may suggest how de Duve's ferociously destructive lysosomal compart-
ment might be tamed, particularly in those cells that elaborate toxic
lysosomes to kill other cells or pathogens.
3. Antigen processing in B lymphocytes
The early studies outlined above demonstrated that antigen uptake
was followedbyaprocessingevent and the association of proteolytically
processed antigenic peptides with class II MHC molecules but many
important questions were left open. In particular, where along the
endocytic pathway did antigen processing take place? How was
processed antigen transferred to class II MHC molecules and at what
point in their biosynthetic itinerary?Howmuch processingwas needed
and bywhichproteases?Were additional chaperones required andhow
similar were the events of antigen processing in macrophages and B
cells? In the late 1980swhen these questions came to the fore, dendritic
cells were already known to be highly immunostimulatory for T cells
[11] but were difﬁcult to expand and work with in vitro. Consequently,
early studies on the cell biology and biochemistry of antigen processing
continued to be performed in B cells and macrophages.
It waswell established that B cells required T cell ‘help’ to drive their
differentiation into antibody secreting cells and eventually it became
clear that, like macrophages, B cells captured antigen, processed it and
reexpressed it linked somehow to MHC molecules. What was unclearwas the role of the B cell antigen receptor (BCR), a membrane anchored
form of antibody. Studies by Grey, Abbas [12, 13] and most deﬁnitively
by Lanzavecchia [14] eventually showed that the BCR was a device for
antigen capture for endo/lysosomal processing but was not involved in
presenting antigen to T cells. In other words, recognition of antigen by B
cells and T cells was sequential not simultaneous as earlier models had
suggested. Human EBV-transformed B cells expressing BCRs speciﬁc for
the tetanus toxin (TT) antigen were shown to present TT to human T
cells at antigen concentrations as low as 10−12 M, four orders of
magnitude lower than that required by B cells that lacked a speciﬁc BCR
for this antigen [14].
I suspected that antigen-speciﬁcB cells couldoffer a valuable systemto
dissect the cell biology and biochemistry of antigen presentation since the
fate of a single cohort of BCR-bound antigenmolecules could be followed
much as the endocytosis and subsequent fate of low density lipoprotein
[15] or transferrin [16, 17] had been followed in the developing ﬁeld of
membraneandreceptor trafﬁcking.Using 125I-labelledTTweshowed that
this antigenwas internalised throughclathrincoatedpits and thatdiscrete
fragments resolvable on SDS-gels were observed after about 20 min [18].
Antonio Lanzavecchia had provided us with several different EBV-
transformed B cell clones speciﬁc for TT. Interestingly, the pattern of
fragmentation was different in each clone and we showed that this was
due to the fact that each had a different epitope speciﬁcity and that the
substrate for processing was the TT/BCR complex and the BCR in each
clone protected or ‘footprinted’ a distinct set of fragments [19]. Later we
showed that this ‘steering’ of antigen processing by the BCR affected the
parts of antigen displayed to T cells on class II MHCmolecules[20]. Thus B
cells with a deﬁned epitope speciﬁcity presented some peptides, and
could therefore collaboratewith certain T cells, better thanothers.Wealso
speculated at this time that the large antigen fragments attached to the
BCR might be simultaneously engaged by local class II MHCmolecules in
the same membrane plane [18] but it took many years before we could
show that this can indeed occur (Fig. 1 and see below). We obtained two
other important results around this time in collaboration with Antonio
Lanzavecchia. First, we showed using both biochemical and T cell assays
that the lifetime of peptide/class II MHC complexes was in most cases
equal to the lifetimeof theMHCmolecules themselveswhich in the caseof
EBV-transformed B cells was 25–35 h [21]. In other words, once formed,
MHC/peptide complexes were very stable permitting antigen captured at
a peripheral site in vivo to be presented in lymphoid tissue several days
later. Second, using a direct biochemical assay for de novo formation of TT
peptide/MHC complexes, we showed that processed antigen was
captured by newly synthesised class MHCmolecules prior to their arrival
on the cell surface [22]. In other words, antigen capture was an integral
part of the biosynthetic itinerary of class IIMHCmolecules and did not, for
the most part, utilise a class II MHC recycling pathway we had recently
demonstrated [23, 24]. This was in good agreement with work from
others showing that class II MHC, but not class I MHC molecules,
intersected the endocytic pathway on theirway to the cell surface [25, 26]
and that class II MHC molecules undergo a conformational change in a
post-ER compartment upon invariant chain dissociation (see below) and
peptide binding [27].
4. Mapping the events of antigen processing and class II MHC
loading onto the endo/lysosomal pathway
An important issue, still not fully resolved, concerns the domains
of the endocytic pathway where antigen processing occurs, where
class II MHC molecules capture peptide and how these complexes are
transported to the cell surface. In 1994, we and the groups of Ploegh
and Mellman identiﬁed and isolated distinct compartments of the
endocytic pathway that hosted peptide loading on class II MHC
molecules [28-30]. We used a strategy in these and later studies ﬁrst
described by Aijoka and Kaplan [31] which permits the ablation of
selected compartments of the endocytic pathway by loading them
with horseradish peroxidase (HRP). By conﬁning HRP to speciﬁc
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to transferrin, compartment-speciﬁc ablation following addition of
peroxide and diaminobenzidine (DAB) can be achieved. The dense
cross-linked precipitate of DAB that forms effectively inactivates the
HRP-containing compartment but remarkably, cellular trafﬁc path-
ways that do not involve this compartment proceed normally, at least
for a time. Using this approach we and the group of Sebastian
Amigorena showed that to get to the site of Ii processing and peptide
loading, class II MHC/Ii complexes must pass through transferrin
receptor positive endosomes but that peptide loading itself occurs in
later compartments [32, 33]. We further showed that, once formed,
the itinerary taken by a speciﬁc assembled peptide/class II MHC
complex to the cell surface did not overlap with itinerary of the
recycling transferrin receptor since ablation of this domain did not
prevent peptide/MHC expression on the cell surface [34]. It was also
shown by Mellman, Amigorena and their colleagues that slowing the
rate of invariant chain processing (see below) drove newlymade class
II MHC molecules deeper into the endocytic pathway suggesting that
the differences that had been reported regarding the types of
endosomes hosting class II MHC molecules might be explained by
variations amongcell types in the rate of invariant chainprocessing [35].
5. Removal of the invariant chain and peptide loading
While we were focussed on antigen processing, others were
studying the biochemistry, genetics and structure of MHC proteins.
Particularly relevant were studies on the biosynthesis and surface
expression of class II MHC molecules. Several labs had shown that
class II MHCα and β chains associated intracellularly with a third sub-
unit named the invariant chain (Ii) but it was the ﬁnding of Blum and
Cresswell that proteolysis is required to remove Ii from its partnerMHC
sub-units that allowed them to speculate that sheddingof Ii, and capture
of processed antigen might take place in the same compartment [36].
Peter Cresswell's lab went on to make the crucial ﬁnding that theFig. 1. Antigen receptor directed antigen processing and ‘handover’ to class II MHC. The carto
BCR bound antigen (grey) with different potential T cell epitopes (coloured ovals) is delivere
proteases. Limited cleavages produce large unfolded segments of antigen that can be capture
phase. Trimming (scissors) reduces the size of MHC associated antigen prior to delivery to t
fragments released into the lumen (orange) have a lower probability of survival and capture
(green). This scenario results in preferential presentation of some T cell epitopes over otheassociation with Ii prevented binding of antigenic peptides to class II
MHC molecules [37] and they further showed that some B lympho-
blastoid cell lines that were defective in antigen presentation,
accumulated Ii fragments on their class II MHC molecules [38]. These
mutants isolated by Pious and others turned out to be in an MHC-like
protein calledDM, inhuman cells, HLA-DM[39]. Laterwork fromseveral
labs showed that human and murine DM catalyses the removal of a
residual fragment of Ii generated following proteolytic processing and
also stabilises the now empty peptide binding groove [40-42].
Moreover, sub-optimal peptides other than the Ii remnant can also be
removedby the action of DMsuch that it acts as a peptide editor, driving
the formation of the long-lived peptide/class II MHC complexes
mentioned earlier [43]. The functions of a second class II MHC-like
dimerHLA-DOhave beenmore difﬁcult to pin downbutmost labs agree
that DO has an inhibitory effect on DM that may be relieved under
particular conditions, for example in the compartments in B cells to
which BCR bound antigen is delivered [44]. Inhibition of DM by DO is
predicted to broaden the range of peptides presented facilitating
tolerance to a greater variety of ‘self’ proteins. Consistent with this,
LisaDenzin's labhas recently shown that diabetes susceptible NODmice
became resistant to the disease when DO was overexpressed in
dendritic cells [45].
6. Antigen processing
Advances in mass spectrometry in the early 1990s allowed several
labs to analyse the peptides eluted from puriﬁed class II MHC
molecules to reveal the peptide output of antigen processing in the
endo/lysosomal pathway. These peptides were not strictly speaking
from exogenous antigen but rather were derived from cellular and
serum proteins that had access to the endocytic pathway. They were
found to be longer and more variable in length than those bound to
class I MHC and frequently featured nested sets, i.e. where a common
core sequence was extended N- and C-terminally to varying degreeson is meant to represent a class II MHC positive endo/lysosomal compartment in a B cell.
d and processing commences whilst the antigen is still bound to the BCR. Scissors denote
d by DM-chaperoned class II MHCmolecules without release of antigen into the lumenal
he cell surface. NB vesicle trafﬁcking steps not shown. The ﬁgure suggests that antigen
than fragments that are tethered by the antigen receptor and are membrane proximal
rs. For experimental evidence see Ref. 18-20, 53.
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peptides form a network of hydrogen bonds with class I MHC residues
located at the ends of the peptide binding groove [48] these
interactions are absent in class II MHC molecules and instead the
12–19 (or longer) residue peptides eluted from puriﬁed class II MHC
molecules protrude beyond the ends of the groove [48]. Our early
biochemical studies on TT processing suggested that even longer
antigen fragments were captured by class II MHC during physiological
processing [22] and others showed that even unfolding of native
antigen could be sufﬁcient to form a complex, with class II MHC,
stimulatory for a CD4 T cell [49]. What then does this say about the
role of proteases in the class II MHC pathway? The main proteases
found in the endo/lysosomal pathway are the cathepsins, some of
which are cysteine proteases (cathepsins S,L,B,C,H and others) and
some aspartyl proteases (cathepsins D & E) [50]. Together with the lab
of Alan Barrett, we described a novel lysosomal cysteine protease with
strict speciﬁcity for cleavage after asparagine residues [51, 52]. This
asparagine endopeptidase (AEP) is homologous to the plant vacuolar
enzyme legumain and is more closely related to the caspases than to
cathepsins. AEP was discovered in antigen presenting cells because it
dominated the processing of a 47kD C-terminal domain of the TT
antigen in vitro (tetanus toxin C fragment or TTCF) when lysosomes
from EBV-transformed B cells were used as a source of proteases. AEP
makes only a few cleavages in TTCF at clearly identiﬁable Asn residues
yet this is sufﬁcient to generate antigen that can bind class II MHC
molecules — further evidence that class II MHC can capture large
antigen fragments [53]. In antigen presentation experiments conducted
in vitro, mutagenesis of these Asn residues in TTCF or genetic ablation or
chemical inhibition of AEP substantially reduced the efﬁciency of
presentation of TTCF [54, 55]. An additional endo/lysosomal processing
enzyme, though not a protease, has been shown to be important for
presentation of some, though not all, T cell epitopes in antigens with
internal disulphide bonds. The enzyme is γ-interferon induced
lysosomal thiol reductase, or GILT and it catalyses the reduction of
disulphide bonds likely rendering antigens containing them more
susceptible to proteolytic processing [56]. Interestingly, Cresswell's lab,
who discovered the role of GILT in class II MHC antigen processing, have
recently shown that it can also be crucial, again for a sub-set of T cell
epitopes, for viral antigens that are ‘cross-presented’ (see below) on
class I MHC molecules [57].
As noted above, in B lymphocytes with high-afﬁnity BCRs, antigen
is processed as a complex with the receptor meaning that some
antigen fragments will be tethered to the membrane surface [19]. We
recently showed, in a system that used the cell surface as a surrogate
antigen processing ‘compartment’, that large AEP-generated frag-
ments of TTCF could be ‘handed over’ to adjacent class II MHC
molecules in the membrane plane, i.e. without release into the bulk
phase [53] much as we suggested many years ago [18]. Whether this
‘handover’ occurs during antigen processing in B cell class II MHC
positive endosomes remains to be seen but conﬁning the processing
and MHC loading reaction to the 2-dimensional membrane plane has
several appealing features (Fig. 1). It likely to result in faster antigen
capture since diffusion into the lumen of the compartment is avoided.
Consequently, it is likely to limit destructive antigen processing and
competition from peptides free in the lumen of the loading
compartment (Fig. 1). It may also explain the preferred relationships
between B and T cell epitopes in protein antigens mentioned earlier.
The late Eli Sercarz was much concerned with issues surrounding the
processing and capture of T cell epitopes in protein antigens and,
along with others promoted a ‘bind ﬁrst trim later’model for antigen
capture by class II MHC, in part to explain his own data on
immunodominance and ‘crypticity’ in protein antigens [58]. In this
model MHC molecules compete with each other for binding to
extended fragments of processed antigen which, once captured, are
then trimmed by further processing. Our recent studies on TTCF
strongly support the ‘bind ﬁrst trim later’ model [53].Our results on AEP and TTCF processing and presentation in vitro
allowed us to propose that a small number of ‘unlocking’ cleavages by
a single protease might generally sufﬁce to generate a substrate for
class II MHC capture [59]. That model is probably true in most cases.
However, this is not to say that even very clear cut relationships
between antigens and processing enzymes discovered in vitro, such as
that between TTCF and AEP, signal an obligatory protease require-
ment in vivo, i.e. in immunised mice. We found recently that AEP
deﬁcient mice still raise effective immune responses to TTCF although
they do so somewhatmore slowly [60]. Two factors can explain why the
in vitro versus in vivo requirements for AEP in TTCF presentation are
different. First, the levels of AEP in antigenpresenting cells in vivo are very
low compared with B cell lines used in vitro so loss of AEP has a smaller
impact. Second, the longer timescaleof T cell activationanddevelopment
of an antibody response in vivo offsets slower antigen processing by less
optimal proteases. In other words, antigen presentation can ‘catch up’
blunting clear cut differences observed in vitro. Overall the antigen
processing requirements in the class II MHC pathway appear to be quite
minimal and quite redundant and a clear instance of an absolute
requirement for a speciﬁc protease remains to be demonstrated.
However, rather few antigens have been studied in protease deﬁcient
mice and other processing events in the endo/lysosome system do show
non-redundant requirements for single enzymes in vivo. For example,
AEP appears to be absolutely required to convert the single chain formsof
cathepsins L, B and H to the two-chain forms that are found in the endo/
lysosomal pathway [61].
7. Destructive antigen processing
Other antigens are preferentially cleaved by proteases other than
AEP but the idea that a single protease making a few cleavages is
sufﬁcient to generate antigen stimulatory for T cells may generally
apply. For example, in the case of the model antigen myoglobin
processing by the aspartyl protease cathepsin D dominates when
puriﬁed lysosomes are used as source of proteases and is sufﬁcient to
release T cell epitopes [62]. To our surprise however, dendritic cells
lacking cathepsin D presented 2 different T cell epitopes in myoglobin
better, not worse, compared with wild type cells. We showed that the
requirement for aspartyl protease activity in cathepsin D null cells was
satisﬁed by the presence of a related but less abundant aspartyl
protease, cathepsin E [62]. Wild type cells simply contained too much
aspartyl protease activity for optimal processing. In related studies Ira
Mellman's lab showed that protein antigens that were resistant to
processing were better immunogens compared with more easily
processed antigens [63]. Taken together, the data suggest, rather
counter-intuitively, that some antigens/vaccines might be made more
immunogenic, or could be given in smaller doses, if they are harder to
process. That could be achieved either by site directed mutagenesis to
remove some processing sites or possibly bymixing the vaccine protein
withprotease inhibitors. Destructive processingmight also compromise
tolerance to ‘self’proteinswhichmust bepresentedeither in the thymus
or under particular conditions in other lymphoid organs to eliminate or
inactivate autoreactive T cells. For example we found, together with
DavidWraith and colleagues, that AEPmakes a cleavage in themiddle of
awell characterised ‘self’ epitope inmyelin basic protein (MBP) that has
been linked to the pathogenic T cell response in multiple sclerosis [64].
Whether or not this AEP cleavage compromises the induction of
tolerance to this epitope in humans is not clear yet.
8. Cross-presentation and ER incorporation into phagosomes
and endosomes
Class I MHC molecules acquire peptides not in the endo/lysosome
pathway but in the endoplasmic reticulum (ER) following import of
proteasome generated peptides through the TAP transporter system
(reviewed in ref [65]). In the canonical class I MHC pathway these
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viral proteins. At ﬁrst the concept that class I and class II MHC
molecules presented peptides from the cytosol/nuclear compartment
and from the endo/lysosomal compartments respectively was
thought to be quite rigid. However, it became clear that while most
cells indeed failed to present exogenous antigens on their class I MHC
molecules, some could, particularly macrophages and dendritic cells
[66]. This ﬁnding helped to explain early experiments by Bevan who
demonstrated ‘cross-priming’ in vivo [67] and second, it could explain
how CD8 T cell responses could be raised to viruses which do not
infect dendritic cells. In other words, given the key role of dendritic
cells in initiating CD8 immune responses to viruses, if class I MHC
could only ever be loaded with peptides made biosynthetically, how
would a response be made to a virus that does not infect DC [68]? By
allowing some professional APC to load their class I MHC molecules
with exogenous protein, virally infected cells, including necrotic or
apoptotic cells, could be taken up by phagocytosis and viral antigens
translocated into the cytosol for entry into the proteasome and TAP-
dependent class I MHC loading pathway. Such a pathway would also
permit CD8 T cell responses to tumour antigens, which are also not
expressed within DC.
We and the lab of Ken Rock provided the direct evidence that
macrophages and DC can translocate exogenous proteins from
macropinosomes and phagosomes into the cytosol [69, 70] but
working out the precise details of cross-presentation has taken
some time and other labs have made the key advances here. A key
development and a very interesting and controversial one in terms of
the cell biology of the endocytic pathway, has centred on the idea that
elements of the ER are incorporated into phagosomes and endosomes
[71-73]. In other words instead of delivering exogenous antigen to the
canonical site of class I MHC loading, the loadingmachinery, including
class I MHC and TAP transporters is delivered to the antigen. To
explain the proteasome-dependency of most cross-presentation,
phagocytosed or endocytosed antigen is proposed to enter the cytosol
transiently for processing and then to be re-imported into the mosaic
ER-phago/endosome compartment [73, 72]. The controversy hasmostly
centred around whether or not the ER is a signiﬁcant contributor to
newly formed phagosomes and endosomes in dendritic cells and
macrophages. Although some groups have not foundmuch evidence for
this [74] there is good functional evidence in living cells that both TAP
and elements of the ER retro-translocation machinery are incorporated
into and function in cross-presentation in dendritic cell endosomes and
phagosomes [75, 76]. Thus in the current view, the ER retrotranslocation
channel Sec61 and the ATPase p97 is used to shuttle antigens out of
mosaic ER/phago/endosomes and TAP is used to shuttle proteasome-
generated peptides back in.
It should also be mentioned that a distinct pathway of cross-
presentation was also described which does not require proteasome
activity or TAP transporters [77]. In this pathway processing within
phagosomes or endosomes generates suitable peptides for loading
onto class I MHC molecules present in those compartments. More
recent work identiﬁed a role for cathepsin S in this pathway [78].
There are many other interesting aspects of cross-presentation that
cannot be covered here including its greater prominence in certain DC
types and preferential access to the ‘cross-presenting’ compartment
by certain surface receptors. For a recent review see [79].
9. Endosomal proteolysis and Toll-like receptor signalling
Toll-like receptors (TLRs) are expressed on many cells and signal
the presence of so called pathogen associated molecular patterns
found, for example, in bacterial cell wall material and viral nucleic
acids. In macrophages and particularly DC, TLR signalling triggers a
variety of responses which direct and enhance the performance of the
adaptive immune system. For example, DC challenged with TLR
ligands increase their rate of antigen uptake and processing,reorganise their cytoskeleton and vacuolar compartments and
increase cell surface expression of MHC molecules and costimulatory
molecules along with the chemokine receptor CCR7 which is required
for DC migration to lymph nodes. This very active area has been
extensively reviewed by ourselves and others [80, 81]. Here I mention
one speciﬁc aspect relating to the theme of this volume: proteolysis.
TLRs 3, 7, 8 and 9 detect speciﬁc conﬁgurations of RNA and DNA that
are often more abundant in bacteria and viruses than in mammalian
cells. For example, TLR9 recognises CpG motifs that are under-
methylated (relative to mammalian DNA) and TLR3 recognises
double-stranded RNA. Apparently to improve discrimination between
pathogen and ‘self’ nucleic acids it turns out that these TLRs signal not
from the plasma membrane but from endosomal compartments
where viral and bacterial nucleic acid is most likely to be released.
Interestingly, for TLR9 to signal efﬁciently it must ﬁrst be proteolyt-
ically processed. Approximately half of the N-terminal ectodomain is
removed upon entry into the endocytic pathway and importantly only
this form of TLR9 can engage the key signalling adaptor MyD88 [82,
83]. Recent studies have begun to identify the proteases responsible:
both AEP and the cathepsins are involved [84]. These are remarkable
results: whereas signalling from growth factor receptors is often
terminated by proteolysis in the endocytic pathway – the EGF
receptor comes immediately to mind – proteolysis turns out to be a
necessary precursor for signalling from TLR9 and probably the other
nucleic acid sensing TLRs as well.
10. Cystatin F may be a ‘cytoprotectant’ in some immune cells
The events of antigen presentation and TLR signalling show that
the hostile and destructive lysosomal environment so vividly
described by Christian de Duve in ‘A Guided Tour of the Living Cell’
is in fact compatible with information generation and signal
processing in the immune system. But how can the hydrolases
found in these compartments be kept under control? Several
mechanisms seem to operate, at least in DC. Many lysosomal
proteases work optimally at acidic pH explaining in part the relatively
benign environment found in ‘early’ endosomes and the increase in
hydrolase activity as the endosome–lysosome pathway is traversed.
Dendritic cells express lower levels of lysosomal proteases than
macrophages reducing the likelihood of antigen destruction [85]. In
addition they recruit the NADPH oxidase NOX2 to alkalinise newly
formed phagosomes, further limiting the action of potentially
destructive proteases and improving antigen cross-presentation
[86]. A further intriguing attenuator of lysosomal proteolysis in APC
is the p41 variant of the more abundant p31 form of the invariant
chain mentioned earlier. The additional 64 amino acids found in p41
acts as an inhibitor of cathepsin L and other endo/lysosomal proteases
[87, 88]. Since p41 is particularly abundant in DC, it may also limit
destructive antigen processing, maximising the chance of successful
presentation of processed antigen. Finally we have recently shown
how an unusual member of the cystatin family of cysteine protease
inhibitors, cystatin F, may also limit protease activity in the endo-
lysosome pathway, not just in DC but in several immune cells types
where it is selectively expressed.
The cystatins are a family of low molecular weight, tight binding
inhibitors of cysteine proteases [89]. Some members are found in the
cytosol but the majority are secreted and found in body ﬂuids and
tissue interstitia where they are proposed to ‘mop up’ inadvertently
released proteases and prevent tissue damage. Cysatin F, also known
as leukocystatin, does not conform to this model. Although it is made
with a signal sequence, only a fraction is secreted, the rest being
targeted to the endo-lysosome pathway [90] due to mannose-6-
phosphate receptor recognition of its N-linked saccharides [91].
Importantly, this material and any that is secreted, is initially inactive.
This is because it is made as a disulphide linked dimer [92] and
partnering with another molecule of cystatin F precludes binding to
Fig. 2. Cystatin F as an attenuator of lysosomal cysteine proteases. Cystatin F (pale
green) dimerises in the ER through di-sulphide linkages (yellow dots) and is
transported to the endocytic pathway using the mannose-6-phosphate targeting
system. Dimer to monomer conversion is driven by proteolytic action (red asterisk) on
an N-terminal linking peptide that contains one of the cysteines involved in the
disulphide bridge. Protease generated monomer has an N-terminus truncated by 15
residues relative to monomer generated by reducing agents in vitro. Since cystatin N-
termini are important in cysteine protease inhibition, this changes the target range of
the monomer. For example, cathepsin C is blocked by protease generated monomer but
not by full-length monomer generated by reduction. Secreted cystatin F can be taken
up, again via mannose-6-phosphate receptors and activated by bystander cells. For
experimental evidence see references 89-95.
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active cystatin F in vitro, high levels of reducing agent are needed [93]
and we recently showed that in living cells inactive dimer to active
monomer conversion is achieved by protease action on the extended
N-terminal regions that link the partner subunits [95]. The discovery
of a protease inhibitor that is itself activated by proteolysis
immediately suggests that cystatin F may provide negative feedback
regulation of excessive protease activity (Fig. 2). But under what
speciﬁc circumstances might this be needed? The cell types that
express cystatin F may offer an important clue. The inhibitor is
expressed in cytotoxic T cells, NK cells, NKT cells, mast cells,
neutrophils, eosinophils and some other cell types. All these cells
elaborate granules, which are in effect lysosomes, that can be secreted
in a regulated manner, to achieve their effector function, for example
killing of target cells or pathogens [96]. The contents of these granules
are toxic suggesting that strategies to limit their activity until required
may be useful to prevent self-inﬂicted injury. Consistent with a role
for cystatin F in such protection, we have found that one of the
protease targets of cystatin F is cathepsin C [95], the cysteine protease
that activates the granzymes in cytotoxic T cells and NK cells and
several of the effector proteases of neutrophils (elastase and cathepsin
G) and mast cells (chymase). We are currently studying the
phenotype of cystatin F null mice to establish its in vivo role.
Finally some cystatin F is secreted and unlikemonomeric cystatins,
will not bind to and therefore be quenched, by proteases outside cells.
Being glycosylated it can be readily taken up through carbohydrate
recognition receptors such as the mannose-6 phosphate receptor and
subsequently activated in the recipient cell [91]. Thus protease
activity may be modulated in trans by cystatin F expressing cells
(Fig. 2) a facility which may permit the attenuation of some of the less
desirable phenomena that have been linked to the cysteine cathepsins
such as inﬂammation and tumour progression.11. Closing summary
Our understanding of the endo/lysosomal pathway has come a
long way since the pioneering studies of de Duve and colleagues.
Complete destruction of material taken into cells by endocytosis, is
certainly not the only and may not even be the most important
function of the endo/lysosome system in many cells. In immune cells
such as DC crucially important information is generated that activates
both the innate and adaptive immune systems. This information
consists of protein fragments that complex with class II MHC
molecules to create a ‘currency’ recognised by the CD4 T lymphocyte
system. Class I MHC molecules can also be loaded in the endocytic
pathway through the still to be fully characterised mechanisms of
cross-presentation which intriguingly, seems to involve incorporation
of limited amounts of ER into phagosomes and endosomes. Some
pathogen sensing TLR receptors are activated by endosomal proteol-
ysis. Finally, the toxic enzymes elaborated by various immune cells
and packaged into lysosome like organelles for discharge onto target
cells may be hazardous to the cell producing them. Cystatins and
perhaps particularly cystatin F, which is itself activated by proteolysis,
may act as a brake and protect cells from their own armoury of toxic
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